Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: Results from a phase III open-label extension trial

Epilepsia

Volumn 53, Issue 3, 2012, Pages 521-528

  Husain, Aatif ^a   Chung, Steve ^b   Faught, Edward ^c   Isojarvi, Jouko ^d,e   McShea, Cindy ^d   Doty, Pamela ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

^c EMORY UNIVERSITY   (United States)

^d UCB PHARMA   (Belgium)

^e NONE

Author keywords

Efficacy; Lacosamide; Long term; Open label; Safety

Indexed keywords

HARKOSERIDE;

ADJUVANT THERAPY; ADULT; ANTICIPATORY NAUSEA AND VOMITING; ANTICONVULSANT THERAPY; ARTICLE; BALANCE DISORDER; BODY WEIGHT; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; CONVULSION; DIPLOPIA; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FALLING; FEMALE; FOCAL EPILEPSY; HEADACHE; HUMAN; IRRITABILITY; LABORATORY TEST; LACERATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NYSTAGMUS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SUICIDAL IDEATION; THORAX PAIN; VITAL SIGN; VOMITING;

ACETAMIDES; ADULT; ANTICONVULSANTS; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; TIME; TREATMENT OUTCOME;

EID: 84857551225     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2012.03407.x     Document Type: Article

References (11)

1. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD,. (2007) Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48: 1308-1317. (Pubitemid 47063096)
2. Biton V, Fountain NB, Rosenow F, Gil-Nagel A, Sullivan T, Hebert D, Doty P,. (2009) Safety and tolerability of lacosamide: a summary of adverse events in epilepsy clinical trials. European Congress on Epileptology-8th. Epilepsia 50 (Suppl. 4): 110.
3. Bootsma HP, Vos AM, Hulsman J, Lambrechts D, Leenen L, Majoie M, Savelkoul M, Schellekens A, Aldenkamp AP,. (2008) Lamotrigine in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 12: 262-268.
4. Brandt C, May TW, Pohlmann-Eden B, Nieder E, Elsner H, Witte-Boelt K, Schuermann I, Ebner A,. (2009) Retention rate of pregabalin in drug-resistant epilepsy: 1-year follow-up, single-centre observation in 105 consecutive, adult patients. Seizure 18: 634-638.
5. Cho YJ, Heo K, Kim WJ, Jang SH, Jung YH, Ye BS, Song DB, Lee BI,. (2009) Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: an observational study. Epilepsia 50: 1910-1919.
6. Chung S, Ben-Menachem E, Sperling MR, Rosenfeld W, Fountain NB, Benbadis S, Hebert D, Isojarvi J, Doty P,. (2010a) Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs 24: 1041-1054.
7. Chung S, Sperling MR, Biton V, Krauss G, Hebert D, Rudd GD, Doty P,. (2010b) Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 51: 958-967.
8. Datta PK, Crawford PM,. (2000) Refractory epilepsy: treatment with new antiepileptic drugs. Seizure 9: 51-57. (Pubitemid 30099237)
9. Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, Rosenow F, Doty P, Hebert D, Sullivan T,. (2009) Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 50: 443-453.
10. Yuen AW, Singh R, Bell GS, Bhattacharjee A, Neligan A, Heaney DC, Duncan JS, Sander JW,. (2009) The long-term retention of pregabalin in a large cohort of patients with epilepsy at a tertiary referral centre. Epilepsy Res 87: 120-123.
11. Zaccara G, Specchio LM,. (2009) Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat 5: 249-259.